Company intelligence / Profile preview

BayRay Innovation Center

Shenzhen, Guangdong, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

BayRay Innovation Center is a leading biotech innovation hub focused on technology-driven drug discovery and development. It has developed at least one broad neutralizing nanobody against SARS-CoV‑2 that competes with human ACE2 to inhibit infection. The center recruits experts in biology, drug delivery, and formulation to support its growth as a major player in innovative therapeutics.

Therapeutic areas: OtherInfectious Diseases
Modalities: Nanobody therapySmall moleculeDrug delivery technologies
Industry: Biotech

Partnerships

No major pharmaceutical partnerships explicitly listed. However, leadership includes individuals with experience at Pfizer Asia Discovery Labs and other global pharma companies, suggesting strong industry connections.

Beyond the preview

Go deeper on BayRay Innovation Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BayRay Innovation Center.

Explore the full profile